DDInter1907 DDInter172
Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic disease-modifying anti-rheumatic drug (bDMARDs) that is used in the management of various inflammatory conditions that involve the activation of IL-12 and IL-23 signalling pathways. The therapeutic use of the drug started in Canada, the US, and Europe since 2009 when it was first approved for the treatment of adult patients with moderate to severe plaque psoriasis and active psoriatic arthritis, alone or in combination with [methotrexate]. In September 2016, ustekinumab was additionally approved for the management of moderate to severe Crohn's disease
Belatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of two homologous polypeptide chains of 357 amino acids each. It is produced through recombinant DNA technology in mammalian CHO cells. The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes. It is approved for the treatment of rheumatoid arthritis. Belatacept selectively blocks the process of T-cell activation. It was developed by Bristol-Myers-Squibb. Belatacept is only 2 amino acids different from abatacept (Orencia). FDA approved on June 15, 2011.
Ustekinumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Ustekinumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Ustekinumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tetracosactide
Ustekinumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olaparib
Ustekinumab {u} may lead to a major life threatening interaction when taken with {v} Sarilumab
Ustekinumab {u} may lead to a major life threatening interaction when taken with {v} Natalizumab
Ustekinumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Ustekinumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Ustekinumab may lead to a major life threatening interaction when taken with Sarilumab
Ustekinumab may lead to a major life threatening interaction when taken with Natalizumab